Eligibility Requirements for Participating in Experimental HIV Therapies HIV Cure Centre

The search for an HIV cure has accelerated over the past decade, bringing hope through experimental therapies such as broadly neutralizing antibodies, gene editing, therapeutic vaccines, latency-reversing agents, immune-based therapies, stem cell strategies, and novel investigational approaches. For people living with HIV, one common question is:

“Am I eligible to participate in an experimental HIV therapy trial?”

The answer depends on strict scientific, medical, ethical, and regulatory criteria. This guide explains the typical eligibility requirements for participating in experimental HIV therapies.

Why Experimental HIV Therapies Have Strict Eligibility Rules

Experimental HIV therapies are research interventions—not standard medical treatment. Their purpose is to test:

Safety
Tolerability
Biological activity
Immune response
Viral reservoir reduction
Long-term remission potential

Because these interventions may involve unknown risks, researchers apply strict inclusion and exclusion criteria to protect participants and ensure scientifically valid results.

Common Eligibility Requirements for Experimental HIV Therapies

1. Confirmed HIV Diagnosis

Participants usually must have:

Documented HIV-1 infection
Confirmatory laboratory diagnosis
Medical records showing infection history

Some studies may focus only on:

Chronic HIV infection
Recently diagnosed individuals
Specific HIV subtypes

Example:
A reservoir reduction trial may only include people with stable chronic HIV infection.

2. Stable Antiretroviral Therapy (ART)

Many HIV cure studies require participants to be on stable ART for a defined period.

Typical requirement:

6 months to 5 years of uninterrupted ART
No recent treatment failure
Good adherence history

Why?

Stable ART minimizes active viral replication and allows researchers to assess whether the experimental therapy affects latent HIV reservoirs.

Common markers:

HIV viral load below detection
Stable CD4 counts
No resistance-related treatment instability

3. Viral Suppression

Many advanced studies require:

Undetectable viral load

Typical definition:

<50 copies/mL
Sometimes <20 copies/mL

Duration required:

6 months
12 months
24 months depending on protocol

This is especially important for:

Analytic treatment interruption (ATI) studies
Functional cure studies
Immune remission protocols

4. CD4 Cell Count Threshold

A minimum immune status is often required.

Typical thresholds:

CD4 >350 cells/mm³
CD4 >500 cells/mm³
Sometimes higher for intensive immune studies

Reason:

Lower CD4 counts may increase risk during experimental interventions.

5. Age Eligibility

Most studies enroll adults:

18–65 years
sometimes 18–55 years

Special pediatric HIV trials have separate ethical approval and eligibility frameworks.

6. No Serious Opportunistic Infections

Participants are commonly excluded if they have:

Active tuberculosis
Cryptococcal infection
CMV disease
Severe bacterial infections
Recent opportunistic illness

Reason:

Experimental immune interventions may worsen unstable infections.

7. No Active Hepatitis or Major Co-Infections

Screening commonly includes:

Hepatitis B
Hepatitis C
Syphilis
Tuberculosis
CMV
EBV in some protocols

Co-infections can:

alter immune responses
increase toxicity risk
confound study outcomes

8. Organ Function Requirements

Participants usually undergo blood tests assessing:

Liver:

AST
ALT
Bilirubin

Kidney:

Creatinine
eGFR

Hematology:

Hemoglobin
WBC count
Platelets

Abnormal organ function may exclude participation.

9. No Significant Cardiovascular Risk (for Some Trials)

Certain immune stimulatory therapies may require:

Normal ECG
Controlled blood pressure
No unstable heart disease

This is especially relevant for cytokine-based or inflammatory immune interventions.

10. No Active Cancer (Unless Cancer-Focused Study)

Standard HIV cure trials may exclude:

lymphoma
leukemia
solid tumors

However, some HIV cure approaches linked with oncology may intentionally include cancer patients.

Example:
Stem cell transplant-associated HIV remission cases emerged in cancer settings.

11. Pregnancy and Reproductive Criteria

Most experimental protocols require:

Not pregnant
Not breastfeeding
Effective contraception

Because fetal safety data are often unavailable.

12. No Immunosuppressive Drug Use

Common exclusions:

corticosteroids
chemotherapy
biologic immunosuppressants
transplant immunosuppressants

These drugs can interfere with immune response measurements.

13. Psychological Readiness

Participation often requires mental readiness for:

uncertainty
repeated hospital visits
invasive procedures
treatment interruption risk

Some protocols include psychological screening.

14. Willingness for Intensive Monitoring

Experimental HIV studies may require:

weekly visits
repeated blood sampling
viral reservoir testing
leukapheresis
biopsies
treatment interruption monitoring

Participation demands substantial commitment.

15. Informed Consent

Every participant must understand:

experimental nature
possible benefits
unknown risks
alternatives
right to withdraw

This is a fundamental ethical requirement.

Special Requirements for Specific HIV Cure Strategies

Gene Editing Trials

Additional screening may include:

genetic eligibility
immune compatibility
absence of malignancy
adequate marrow function

Examples:

CRISPR-based studies
CCR5 editing approaches

Therapeutic Vaccine Studies

May require:

specific HLA types
defined immune responsiveness
viral suppression

Broadly Neutralizing Antibody Studies

May assess:

viral sensitivity
ART history
neutralization profile

Analytic Treatment Interruption (ATI) Trials

Strictest criteria often apply.

Requirements may include:

prolonged viral suppression
strong CD4 counts
rapid access to ART restart
close follow-up

ATI intentionally pauses ART under controlled research conditions.

Where Does Prakasine Fit?

Emerging investigational approaches are also being explored in HIV cure research.

Prakasine, described as a novel non-toxic mercury-based nanomedicine, is being explored as an investigational immunomodulatory approach with reported preclinical and preliminary research observations related to immune activation and anti-HIV biological activity.

At present, Prakasine is not an approved HIV therapy and would require appropriate regulatory approvals and formal clinical trial pathways before standard participant enrollment criteria can be defined.

Potential future eligibility would likely depend on: